Pacific Edge Secures Medicare Draft Coverage for Urine-Based Bladder Cancer Tests Ahead of 2026 Shareholder Meeting

Medicare Draft Coverage Establishes Pacific Edge as Exclusive Urine Biomarker Provider

In its company update, Pacific Edge revealed that on 14 May 2026, Medicare Administrative Contractor Novitas published a draft Local Coverage Determination (DL40378) concerning "Urine-based Biomarkers in Patients with Microhematuria." The draft policy recommends reimbursement for both Cxbladder Triage and Triage Plus tests, marking their first explicit consideration for Medicare coverage. Notably, these are the only biomarkers named for reimbursement under the draft, positioning Pacific Edge as the sole provider of covered urine-based biomarker testing for this critical patient group.

Chair Simon Flood described this as a "Company defining milestone" that "deepens the moat around our business and provides a strong foundation from which to grow." The draft LCD validates Pacific Edge's extensive clinical evidence program and addresses a significant hurdle to US market adoption: Medicare reimbursement uncertainty. Prior to this, the company navigated a period of "Medicare uncertainty," influencing its FY26 capital management. The draft LCD publication fundamentally transforms the reimbursement outlook, paving the way for commercial expansion.

Anticipated Final Medicare Decision and Regulatory Timeline in 2026

Pacific Edge expects a final Medicare Local Coverage Determination to be published before the end of calendar year 2026. While the company did not specify the timeline between draft and final decisions or detail the comment and review process, this guidance signals shareholders can expect regulatory clarity on reimbursement within the year, potentially enabling immediate US market commercialisation.

FY26 capital management was characterised as "careful and prudent," reflecting the uncertainty before the draft LCD. Management intends to maintain this cautious approach until the final determination, balancing opportunity capture with cash prudence. The company stated, "in the new financial year, we are maintaining this stance" and acknowledged that "we are not yet through the Medicare process," indicating ongoing vigilance despite positive draft progress.

Strategic Investment Plans to Leverage Enhanced Market Position

Following the draft Medicare coverage announcement, Pacific Edge signalled selective capital deployment. Chair Simon Flood noted the company now has "a clearer reimbursement pathway, encouraging APAC momentum, a targeted US commercial strategy, growing payer support, and a clinical evidence program that will continue to deliver practice-changing clinical evidence." The company plans "a series of selective investments to capitalise on the opportunities we now enjoy" while focusing on "translating those advantages into growth, reimbursement and a path to profitability."

This indicates Pacific Edge views the Medicare draft decision as a catalyst to expand beyond the US market. The mention of "encouraging APAC momentum" suggests simultaneous advancement in Asia-Pacific markets, leveraging Medicare validation as evidence of clinical utility and payer acceptance to accelerate adoption in other developed healthcare systems. Investments remain selective, reflecting capital constraints and a focus on demonstrating commercial traction before aggressive expansion.

FY26 Financial Results Demonstrate Conservative Capital Management Amid Reimbursement Uncertainty

The company reported that FY26 financial results "reflected careful and prudent management of capital through a period of Medicare uncertainty." Although specific revenue, expenses, or balance sheet data were not disclosed, this indicates a prioritisation of cash preservation over growth investments before the draft LCD. Detailed financial performance is available in the Annual Report and Q1 27 quarterly update.

Maintaining conservative capital management into the new financial year, despite the draft Medicare progress, underscores management’s view that reimbursement remains incomplete until final determination. This approach may reassure shareholders focused on cash runway and balance sheet strength, though it may temper expectations for rapid commercial acceleration. The company emphasises that final Medicare resolution is essential before pursuing aggressive capital deployment.

Director Elections and Board Stability at 2026 Annual Meeting

The 2026 Annual Shareholders' Meeting will feature election and re-election of two directors. Independent Director Bryan Williams is retiring per NZX Listing Rule 2.7.1 and seeks re-election. Chair Simon Flood, appointed during the year, also retires under the same rule and offers himself for election. Both are eligible, with the Board recommending shareholder approval.

This will be Simon Flood's "first Annual Shareholders' Meeting as Chair and Director," and he expressed enthusiasm about engaging shareholders and discussing the company’s significant progress and future opportunities. Electing Board members amid strategic and regulatory advances allows shareholders to evaluate leadership continuity at a critical juncture.

Ratification of 212.6 Million Shares Issued in Recent Capital Raise

Shareholders will vote to ratify issuance of 212,559,717 shares under two NZX Listing Rule frameworks. Resolution 5 seeks approval of 152,561,001 shares issued under Rule 4.5.1, including placement shares, retail offer shares, and shares issued for professional services. Resolution 6 covers 59,998,716 shares issued to retail offer participants under Rule 4.3.1(c).

The announcement did not disclose total capital raised, placement price, or proceeds allocation between operational funding and fees. The structured capital raise includes institutional and retail components, with equity compensation for advisers. This significant dilution event requires shareholder ratification under NZX rules.

Director Remuneration Adjustment During Board Transition

Resolution 4 requests shareholder approval for a $12,699 cash payment to Simon Flood for unpaid director fees accrued from 19 December 2025 to 31 March 2026. This modest amount relates to timing of Flood’s Board appointment and fee accrual during FY26 year-end. Approval is required under NZX Listing Rule 2.11.1 governing director remuneration.

This administrative governance matter reflects regulatory discipline in director compensation during board transitions. The covered period aligns with Flood assuming the Chair role. Seeking shareholder approval for this adjustment highlights Pacific Edge’s formal governance standards.

Auditor Reappointment and Fee Authority for PricewaterhouseCoopers

Resolution 1 authorises the Board to fix audit fees for PricewaterhouseCoopers, automatically reappointed under section 207T of the New Zealand Companies Act 1993. Auditor remuneration for FY26 or guidance for FY27 was not disclosed. PwC’s reappointment and fee delegation are standard annual governance matters.

The Board unanimously recommends voting in favour of Resolution 1, indicating no concerns regarding the auditor relationship or compensation. Delegating fee-setting to the Board allows management flexibility while maintaining oversight. This resolution is routine and uncontroversial.

Hybrid Shareholder Meeting with Online Voting and Real-Time Q&A

Pacific Edge’s 2026 Annual Shareholders' Meeting will be held in a hybrid format on Thursday, 20 August 2026 at 2pm NZ time at MUFG Corporate Markets Board Room, Level 30, PwC Tower, 15 Customs Street West, Auckland 1010. Shareholders may attend virtually via www.virtualmeeting.co.nz/peb26 to watch live, vote online, and submit questions in real time.

In-person attendees are encouraged to RSVP via Eventbrite (Pacific Edge ASM 2026) for catering, though RSVP is optional. Shareholders unable to attend in person or online may appoint proxies and submit votes at vote.cm.mpms.mufg.com/PEB or by proxy form. Proxy and voting deadlines are 2pm Tuesday, 18 August 2026, with voting entitlements set at 5pm the same day. The Virtual Meeting Guide online provides detailed participation instructions.

Pacific Edge’s Urine-Based Diagnostic Platform and Clinical Evidence Focus

Pacific Edge specialises in urine-based biomarker tests for bladder cancer detection and risk stratification. Its main products, Cxbladder Triage and Cxbladder Triage Plus, are non-invasive tests aiding clinical decisions in patients with microhematuria—a common symptom potentially indicating bladder cancer but also present in benign conditions. These tests help reduce unnecessary invasive procedures in low-risk patients and enable earlier detection in higher-risk groups.

The company’s strategy emphasises building robust clinical evidence demonstrating improved patient outcomes and healthcare efficiency. The draft Medicare coverage explicitly references this strong evidence base, validating years of clinical research. Pacific Edge operates across North America, Asia-Pacific, and Europe, with the US market a key focus given its large microhematuria population and historical reimbursement barriers. The Medicare validation is expected to accelerate commercial traction in developed and emerging Asia-Pacific markets.

Shareholder Meeting Timing and Outlook on Strategic Milestones

The 2026 Annual Shareholders' Meeting in late August offers shareholders a chance to review FY26 financials and governance at a critical company juncture. Detailed financial and operational results are available in the Annual Report and Q1 27 quarterly update on https://www.pacificedgedx.com/. Chair Simon Flood indicated the Board and management will update shareholders on "significant progress and opportunities ahead," framing the meeting as a forum to discuss the draft Medicare determination’s strategic impact and plans for commercial growth.

Forward guidance is limited to expecting a final Medicare decision before year-end 2026, marking a key near-term regulatory milestone. No specific revenue, market share, or profitability targets were provided. Management describes its approach as focused on "translating" regulatory and market advantages "into growth, reimbursement and a path to profitability," indicating a measured, evidence-driven commercial rollout rather than aggressive expansion. Investors may seek further insights on adoption assumptions, pricing, market share, and capital needs during the meeting.